Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (261-270 of 300) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Hematological Oncology|October 7, 2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) CohortJames R Cerhan, Tereza Sokolova, Elliott J Cahn, et al.
Pageof 30

Showing results (261-270 of 300) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Hematological Oncology|October 7, 2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) CohortJames R Cerhan, Tereza Sokolova, Elliott J Cahn, et al.
Pageof 30